HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight’s Consumer Health Product Sales Spared From Pandemic Plummet In Q2

Executive Summary

C&D said sales of its brands including vitafusion, L’il Critters and PB8 supplements, Arm & Hammer, Aim and Close-Up toothpastes and Waterpick and Spinbrush power toothbrushes helped drive 8.8% growth to $386.4m for the personal and health care categories.

You may also be interested in...



US Q2 Consumer Health Earnings Preview: Will More Favorable Year-Ago Comparisons Help?

April-June sales of OTC drugs, supplements and personal care products likely will show at least notable and potentially strong increases from year-ago period when consumers slowed spending after splurging during 2020 Q1 as novel coronavirus pandemic sent shockwaves through the marketplace.

Church & Dwight Lifts Curtain On 2021: Halle Berry For Flawless, Vitafusion In Cough/Cold Aisle

Emerging markets expected to be growth drivers across C&D’s supplement, OTC drug and household care product lines in 2021. Super Immune formulation with more than 100% daily value of vitamin C, zinc and elderberry and Manuka honey is first vitafusion product in cough/cold aisle and brand's first extension for 2021.

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel